We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Sarah Sloat
Swiss pharma company Roche said Friday it has received a positive opinion from the European Union that would extend use of its Evrysdi treatment for babies diagnosed with spinal muscular atrophy.
The positive recommendation from the EU Committee for Medicinal Products for Human Use, or CHMP, is based on interim data from an ongoing trial that showed most babies treated with Evrysdi were able to stand and walk within timeframes typical of healthy babies by 12 months of treatment, Roche said.
Evrysdi is currently approved in the EU for treating patients two months or older.
Specifically the recommendation to extend marketing authorization includes treatment for infants with genetically confirmed diagnosis of different types of spinal muscular atrophy from birth to below two months.
Write to Sarah Sloat at sarah.sloat@wsj.com
(END) Dow Jones Newswires
July 21, 2023 10:10 ET (14:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
